122 related articles for article (PubMed ID: 9545814)
1. [Long-term follow up of aggressive lymphoma patients treated with CAMBO-VIP--clinical significance of a residual mass after otherwise successful chemotherapy].
Okamoto M
Rinsho Ketsueki; 1998 Feb; 39(2):111-2. PubMed ID: 9545814
[No Abstract] [Full Text] [Related]
2. [CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study].
Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
Gan To Kagaku Ryoho; 1994 Jan; 21(1):67-73. PubMed ID: 7507314
[TBL] [Abstract][Full Text] [Related]
3. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
4. Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
Björkholm M; Celsing F; Johansson E;
Ann Hematol; 2006 Oct; 85(10):731-3. PubMed ID: 16838163
[No Abstract] [Full Text] [Related]
5. [Recent progress in the chemotherapy program and its theoretical background--malignant lymphoma].
Hirano M; Okamoto M; Maruyama F; Ezaki K
Nihon Rinsho; 1992 Jun; 50(6):1393-9. PubMed ID: 1381450
[TBL] [Abstract][Full Text] [Related]
6. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
7. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
[TBL] [Abstract][Full Text] [Related]
10. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy in advanced non-Hodgkin's lymphoma: follow-up studies].
Kimura I
Nihon Rinsho; 1983 Nov; 41(11):2600-10. PubMed ID: 6200629
[No Abstract] [Full Text] [Related]
14. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
Adde M; Shad A; Venzon D; Arndt C; Gootenberg J; Neely J; Nieder M; Owen W; Seibel N; Wilson W; Horak ID; Magrath I
Semin Oncol; 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PubMed ID: 9578060
[TBL] [Abstract][Full Text] [Related]
15. Non-hodgkins lymphoma.
Mead G; Woodcock J; Young C
Clin Evid; 2003 Jun; (9):1-21. PubMed ID: 12967352
[No Abstract] [Full Text] [Related]
16. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
18. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
19. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of dose density therapy in patients with aggressive lymphoma.
Fridrik MA; Hausmaninger H; Linkesch W; Greil R; Krieger O; Baldinger C; Klocker J; Pont J; Oberaigner W
Ann Hematol; 2005 Apr; 84(4):217-22. PubMed ID: 15538568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
